SU-FF-T-520: Is IMRT Better Than 3D Conformal Therapy for Prostate Cancer? A Radiobiological Comparison

2009 ◽  
Vol 36 (6Part17) ◽  
pp. 2643-2643
Author(s):  
S Stathakis ◽  
C Buckey ◽  
P Mavroidis ◽  
G Swanson ◽  
D Mihailidis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Conformal Therapy ◽  
Better Than

scholarly journals Increases in Quantitative D-Dimer Levels Correlate With Progressive Disease Better Than Circulating Tumor Cell Counts in Patients With Refractory Prostate Cancer

2010 ◽  
Vol 134 (6) ◽  
pp. 964-969 ◽  
Author(s):  
Joseph D. Khoury ◽  
Dorothy M. Adcock ◽  
Fanny Chan ◽  
James T. Symanowski ◽  
Stefan Tiefenbacher ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Cell ◽  
Progressive Disease ◽  
Circulating Tumor Cell ◽  
Cell Counts ◽  
D Dimer ◽  
Better Than

scholarly journals Evaluation of Peripheral Zone Prostate Cancer Aggressiveness Using the Ratio of Diffusion Tensor Imaging Measures

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Aslihan Onay ◽  
Gokhan Ertas ◽  
Metin Vural ◽  
Omer Acar ◽  
Yesim Saglican ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diffusion Tensor Imaging ◽  
Diffusion Tensor ◽  
Mean Diffusivity ◽  
Peripheral Zone ◽  
Strong Correlations ◽  
Noncancerous Tissue ◽  
Statistical Measures ◽  
Cancer Aggressiveness ◽  
Better Than

Purpose. To evaluate the aggressiveness of peripheral zone prostate cancer by correlating the Gleason score (GS) with the ratio of the diffusion tensor imaging (DTI) measures. Materials and Methods. Forty-two peripheral zone prostate tumors were imaged using DTI. Regions of interest focusing on the center of tumor foci and noncancerous tissue were used to extract statistical measures of mean diffusivity (MD) and fractional anisotroy (FA). Measure ratio was calculated by dividing tumor measure by noncancerous tissue measure. Results. Strong correlations are observable between GS and MD measures while weak correlations are present between GS and FA measures. Minimum tumor MD (MDmin) and the ratio of minimum MD (rMDmin) show the same highest correlation with GS (both ρ=-0.73). Between GS ≤ 7 (3 + 4) and GS ≥ 7 (4 + 3), differences are significant for all MD measures but for some FA measures. MD measures perform better than FA measures in discriminating GS ≥ 7 (4 + 3). Conclusion. Ratios of MD measures can be used in evaluation of peripheral zone prostate cancer aggressiveness; however tumor MD measures alone perform similarly.

Evaluation of bone metastasis of castration-resistant prostate cancer after enzalutamide and abiraterone using Bone Scan Index on bone scintigraphy.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. e596-e596
Author(s):  
Suguru Kadomoto ◽  
Kouji Izumi ◽  
Takahiro Nohara ◽  
Konaka Hiroyuki ◽  
Yoshifumi Kadono ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Bone Metastases ◽  
Bone Scintigraphy ◽  
Bone Scan ◽  
Average Rate ◽  
Castration Resistant Prostate Cancer ◽  
Bone Scan Index ◽  
Castration Resistant ◽  
Better Than

e596 Background: It was ambiguous till now to evaluate the change of bone metastasis by various treatments. To quantify the change of bone metastases by enzalutamide, abiraterone, and docetaxel for the castration-resistant prostate cancer (CRPC) with bone metastases (bmCRPC), we employed Bone Scan Index (BSI) on bone scintigraphy. Methods: We retrospectively evaluated the change of PSA and bone metastases of CRPC patients who were treated with enzalutamide (Enz), abiraterone (Abi) and/or docetaxel (DOC) in our hospital. All patients underwent Tc-99m MDP bone scintigraphy. The degree of bone metastases was analyzed using BSI, which was calculated by BONENAVI (FUJIFILM RI Pharma, Japan; EXINIbone, EXINI Diagnostics, Sweden). 19 patients were treated with enzalutamide (8 cases: pre-docetaxel, 11 cases: post-docetaxel). The median PSA of patients treated with Enz was 12.64 ng/ml (1.63-199 ng/ml). And 11 patients were treated with abiraterone (5 cases: pre-docetaxel, 6 cases: post-docetaxel). The median PSA of patients treated with Abi was 26.37 ng/ml (2.29-199 ng/ml). Results: We observed decline of PSA in 18/30 cases (9 cases: pre-DOC, 9 cases: post-DOC). Decline of PSA to 50% or more was observed in 14 cases. In contrast, decline of BSI was observed in 53.3% (16/30) cases and decline of PSA to 25% or more was observed in only 6 cases. BSI decreased in 84.6% (11/13) of pre-DOC setting and in 29.4% (5/17) of post-DOC setting indicating that change of BSI was poor in post-DOC setting. However, DOC had already decreased BSI in 91.7% (11/12) before Abi or Enz treatment. Moreover, the average rate of BSI decline in the patients that BSI decreased by DOC was better than the patients that BSI decreased by Abi/Enz (-48.46% vs -28.56%). Finally, although the rate of BSI change by Enz was weakly correlated with the rate of PSA decline (y = 0.3906x + 25.35, R2 = 0.3423), BSI continued to increase in four cases in spite of PSA decline. Conclusions: BSI using BONENAVI on bone scintigraphy was helpful for evaluating the effectiveness of treatment and following-up of bmCRPC.

scholarly journals Transurethral Resection of Prostate for the Treatment of Advanced Prostate Cancer and Bladder Outlet Infarction

1970 ◽  
Vol 1 (2) ◽  
Author(s):  
Chenglin Huang
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Endocrine Therapy ◽  
Transurethral Resection ◽  
Advanced Prostate Cancer ◽  
Control Group ◽  
Transurethral Resection Of Prostate ◽  
Study Group ◽  
Better Than

Objective: To investigate the feasibility of transurethral resection of prostate and the treatment of advanced prostate cancer and bladder outlet infarction, and to analyze the therapeutic effect. Methods: 34 patients with advanced prostate cancer admitted in our hospital from April 2014 to April 2014 were divided into control group (17 cases) with routine endocrine therapy. The study group (17 cases) underwent urethral resection surgery Combined with endocrine therapy, through the relevant indicators of prostate treatment were observed to explore the two groups of patients with therapeutic effect. Results: According to the related indexes of prostate treatment, the treatment effect of the study group was significantly better than that of the control group, and the data of the two groups were statistically significant (P<0.05). Conclusion: The treatment of advanced prostate cancer patients with endocrine combined with transurethral resection of the prostate can effectively treat the symptoms of bladder outlet infarction and improve the quality of life of patients. It has certain value in clinical treatment.

Sign in / Sign up

Export Citation Format

Share Document